MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- Captivision Inc. (“Captivision” or the “Company”) (NASDAQ: CAPT), a pioneering manufacturer and global LED solution provider, announced that on June 4, 2025, it received a staff determination letter (the “Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had not regained compliance with the Market Value of Listed Securities (“MVLS”) Requirement by June 2, 2025. The Determination L ...

Company Overview - Broadway Technology Inc ("Gaokai") is a leading manufacturer of high-quality PET (polyethylene terephthalate) cups and lids through its subsidiary Zhejiang Gaokai New Materials Co., Ltd [1] - Established in 2021, Gaokai specializes in customized PET products used in various packaging markets, including aviation, yogurt, juice, fruit tea, coffee, and cold beverages [3] - The company operates within a PET industrial park in Haining, Zhejiang Province, facilitating the sourcing and development of advanced PET raw materials [3] Competitive Advantages - Gaokai's core competitive advantages include stable and high-performance raw PET materials, comprehensive upstream sheet manufacturing capabilities, advanced equipment, and automated production lines [4] - The company offers extensive PET cup customization services, including advanced printing technology for custom logos, sizes, and shapes [4][5] Business Combination Details - Gaokai is set to merge with Quartzsea Acquisition Corporation, a publicly traded special purpose acquisition company, under a Merger Agreement [1][2] - Upon completion of the transaction, Gaokai will become a wholly owned subsidiary of Cuisine Universal Packaging Solution, which will be listed on Nasdaq under the ticker symbol "CUPS" [2][6] - The transaction has been unanimously approved by the boards of directors of both Quartzsea and Gaokai and is subject to regulatory approvals and shareholder approvals [7] Transaction Terms - Under the Merger Agreement, Gaokai's shareholders will receive ordinary shares of Cuisine Universal, with certain shares subject to lock-up agreements for 180 days post-transaction [6] - The transaction is contingent upon the effectiveness of a registration statement by the U.S. Securities and Exchange Commission (SEC) and Nasdaq's approval of the listing application [7]

Core Viewpoint - Magnetic North Acquisition Corp. is currently under a management cease trade order due to its inability to file audited annual financial statements for the year ended December 31, 2024, by the required deadline of April 30, 2025, but expects to file these documents by June 30, 2025 [1][2]. Group 1 - The management cease trade order (MCTO) was granted by the Alberta Securities Commission on May 9, 2025, following the company's default announcement on May 8, 2025 [1]. - The company is committed to satisfying the alternative information guidelines under NP 12-203 and will issue bi-weekly default status reports until the filing delay is resolved [2]. - There are no anticipated specified defaults or insolvency proceedings affecting the company at this time [2]. Group 2 - Magnetic North Acquisition Corp. invests and manages businesses on behalf of its shareholders, emphasizing that capital alone does not guarantee success [3]. - The company operates offices in Calgary and Toronto and has a management team with significant expertise in management, operations, and capital markets [3]. - Magnetic North's common and preferred shares are traded on the TSX Venture Exchange under the symbols MNC and MNC.PR.A, respectively, and it was recognized as a "2021 TSX Venture 50" recipient [3].

Group 1 - SRQ Resources Inc. announced the election of all nominees listed in the management proxy circular as directors during the annual general meeting held on June 6, 2025, with 8,413,589 common shares represented, accounting for 18.25% of the total issued and outstanding shares [1][2]. - The six nominees elected received the following votes: Marc-Antoine Audet received 100% of votes for, while Matthieu Bos received 99.82%, and the other nominees received between 98.53% and 98.53% for their respective votes [2]. Group 2 - Pricewaterhouse Coopers LLP was approved as the external auditors for the upcoming year, with the directors authorized to fix their remuneration [3]. Group 3 - An ordinary resolution was passed to ratify the grant of 1,430,000 options to officers, directors, employees, and consultants, with 1,200,000 options granted to insiders [5][6].

Core Viewpoint - Opendoor Technologies Inc. is seeking shareholder approval for a reverse stock split to support long-term shareholder value and maintain its Nasdaq listing [2][3]. Group 1: Company Actions - The Board of Directors has proposed a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-50, with the exact ratio to be determined by the Board [2]. - The decision to implement the reverse stock split will depend on various factors, including market conditions and the trading price of the common stock [3]. Group 2: Company Background - Opendoor is a leading e-commerce platform for residential real estate transactions, aiming to provide a simple and certain way for people to buy and sell homes [5]. - The company has been operational since 2014 and currently serves markets across the United States [5]. Group 3: Upcoming Events - A Special Meeting of Stockholders is scheduled for July 28, 2025, at 9:30 a.m. Pacific Time to discuss the proposed amendments [1][4].

Core Viewpoint - Rakovina Therapeutics Inc. has successfully closed a non-brokered private placement, raising gross proceeds of $4,905,150 to support its innovative cancer therapies and AI-driven drug discovery initiatives [1][7]. Private Placement Details - The private placement includes $3,555,150 from equity units (Units) and $1,350,000 from convertible debenture units (Debenture Units) [1][2]. - Each Unit is priced at $0.05 and consists of one common share and one warrant, allowing the purchase of an additional common share at $0.10 for 24 months [2]. - Each Debenture Unit comprises a $50,000 unsecured convertible debenture and 100,000 warrants, with the warrants allowing the purchase of a common share at $0.15 for 24 months [3]. Financial Terms - The debentures will accrue interest at 12% per annum and are repayable in 36 months, with an option for conversion into common shares at $0.10 [3]. - The company paid cash finder's fees totaling $60,035.50 and issued 1,200,710 finder's warrants, each allowing the purchase of a common share at $0.10 for 24 months [4]. Insider Participation - Insiders subscribed for 14,700,000 Units, generating $735,000 in gross proceeds, which is considered a related party transaction [5]. - The company is relying on exemptions from formal valuation and minority shareholder approval requirements under MI 61-101 [5]. Share Consolidation - A 10-for-1 share consolidation is planned following the private placement, with all amounts presented on a pre-consolidation basis [6]. Use of Proceeds - Proceeds from the financing will support the integration of AI-driven drug discovery tools and enhance visibility among institutional investors in U.S. and global capital markets [7][8]. Investor Relations and Marketing - Rakovina has engaged Fairfax Partners as its Investor Relations partner and Machai Capital for corporate communication services [9]. - Fairfax will implement a three-month IR program with a budget of $250,000, focusing on online marketing and social media [10]. - Machai Capital will enhance marketing campaigns with a budget of $250,000, utilizing various digital marketing strategies [11]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI technologies for targeting DNA-damage response [13]. - The company aims to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners [14].

Core Points - TELA Bio, Inc. announced the approval of an inducement grant of stock options and restricted stock units to Jim Hagen, the Senior Vice President of Strategic Commercial Operations, as part of his employment compensation [1][2] - The stock options have an exercise price of $1.42 per share, with a ten-year term and a vesting schedule over four years [2] - TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's own anatomy [3] Summary by Category Inducement Grant Details - The Compensation Committee approved an option to purchase 75,000 shares and restricted stock units covering 30,000 shares for Jim Hagen [1] - The stock options will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following 36 months [2] - The restricted stock units will vest in equal annual installments over four years [2] Company Overview - TELA Bio is a commercial-stage medical technology company [3] - The company aims to provide advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response [3] - TELA Bio minimizes long-term exposure to permanent synthetic materials in its solutions [3]

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning o ...

New York, NY , June 06, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that on June 5, 2025, it caused to be deposited $0.15 per public share, totaling $10,890.15 (the “Extension Payment”) into its trust account (the “Trust Account”) with Continental Stock Transfer and Trust Company (“Continental”) to extend the deadline to complete its initial business combination from June 9, 20 ...

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the G ...